Medications for Chronic Obstructive Pulmonary Disease

28 results

  • acetylcysteine

    (Acetylcysteine)
    Somerset Therapeutics, LLC
    Acetylcysteine solution, USP is indicated as adjuvant therapy for abnormal mucous secretions in chronic and acute bronchopulmonary diseases, pulmonary complications of cystic fibrosis, tracheostomy care, surgical pulmonary complications, anesthetic use, post-traumatic chest conditions, atelectasis due to mucous obstruction, and diagnostic bronchial studies.

  • advair

    (fluticasone propionate and salmeterol)
    Rebel Distributors Corp.
    ADVAIR DISKUS is indicated for treating asthma in patients aged 4 and older, and for the maintenance treatment of chronic obstructive pulmonary disease (COPD). It is not for acute bronchospasm relief and should be prescribed to patients inadequately controlled on long-term asthma medications or with severe disease.

  • advair diskus

    (fluticasone propionate and salmeterol)
    A-S Medication Solutions
    ADVAIR DISKUS is indicated for the twice-daily treatment of asthma in patients aged 4 and older, and for the maintenance treatment of chronic obstructive pulmonary disease (COPD) to improve airflow and reduce exacerbations. It is not intended for acute bronchospasm relief.

  • albuterol sulfate

    (Albuterol Sulfate)
    NuCare Pharmaceuticals,Inc.
    Albuterol sulfate inhalation solution is indicated for relieving bronchospasm in patients aged 2 years and older with reversible obstructive airway diseases and during acute bronchospasm attacks.

  • arformoterol tartrate

    (Arformoterol Tartrate)
    Sun Pharmaceutical Industries, Inc.
    Arformoterol tartrate inhalation solution is indicated for long-term maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema, administered via nebulization. It is not for acute COPD exacerbations or for treating asthma.

  • arformoterol tartrate

    (Arformoterol Tartrate)
    Ingenus Pharmaceuticals, LLC
    Arformoterol tartrate inhalation solution is indicated for the long-term maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD). It is not intended for acute exacerbations or for asthma treatment. Administration is via nebulization, twice daily.

  • budesonide and formoterol fumarate dihydrate

    (Budesonide and Formoterol Fumarate Dihydrate)
    A-S Medication Solutions
    Budesonide and Formoterol Fumarate Dihydrate Inhalation Aerosol is indicated for asthma treatment in patients 6 years and older, and for the maintenance treatment of COPD to reduce airflow obstruction and exacerbations. It is not intended for acute bronchospasm relief.

  • duaklir pressair

    (aclidinium bromide and formoterol fumarate)
    AstraZeneca Pharmaceuticals LP
    DUAKLIR PRESSAIR is prescribed for the maintenance treatment of chronic obstructive pulmonary disease (COPD). It combines aclidinium bromide, an anticholinergic, with formoterol fumarate, a long-acting beta-agonist (LABA). It is not intended for acute bronchospasm relief or asthma treatment.

  • fluticasone propionate and salmeterol

    (fluticasone propionate and salmeterol)
    A-S Medication Solutions
    Fluticasone Propionate/Salmeterol DISKUS is indicated for twice-daily treatment of asthma in patients aged 4 and older who are not adequately controlled on ICS, and for maintenance treatment of COPD to improve airflow and reduce exacerbations. It is not for acute bronchospasm relief.

  • fluticasone propionate and salmeterol

    (fluticasone propionate and salmeterol)
    Preferred Pharmaceuticals Inc.
    Fluticasone propionate and salmeterol inhalation powder is indicated for the twice-daily treatment of asthma in patients aged 4 years and older, and for the maintenance treatment of COPD. It is not for acute bronchospasm relief and is intended for patients inadequately controlled on other medications.